title: Circulating 25-hydroxyvitamin D and risk of endometrial cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers.
abstract: A nested case-control study, including 830 cases and 992 controls from 7 cohorts, was conducted to evaluate the association of circulating 25-hydroxyvitamin D (25(OH)D), the best indicator of vitamin D status, with risk of endometrial cancer. Matching factors included age at blood donation, date of blood donation, and race. Conditional logistic regression was used in the main analysis. The median concentration of 25(OH)D was slightly lower in cases (49.4 nmol/L) than in controls (50.8 nmol/L) (P = 0.08). However, there was no association between 25(OH)D concentration and disease risk, after adjustment for body mass index. Compared with the 50-<75 nmol/L 25(OH)D category, the body mass index-adjusted odds ratios and 95% confidence intervals were 1.08 (95% confidence interval: 0.73, 1.57) for the <25 nmol/L category and 0.90 (95% confidence interval: 0.51, 1.58) for the > or =100 nmol/L category (P(trend) = 0.99). Similarly null results were observed after further adjustment for other known risk factors and in stratified analyses. Although an effect of circulating 25(OH)D at high concentrations cannot be ruled out (the highest category of 25(OH)D was > or =100 nmol/L, and for stratified analyses, > or =75 nmol/L), these results do not support a protective role of vitamin D against endometrial cancer.
authors.affiliation: Department of Environmental Medicine and Cancer Institute, New York University, New York, 10016-3240, USA. anne.jacquotte@nyumc.org
authors.forename: Anne
authors.initials: A
authors.lastname: Zeleniuch-Jacquotte
authors.forename: Lisa
authors.initials: L
authors.lastname: Gallicchio
authors.forename: Virginia
authors.initials: V
authors.lastname: Hartmuller
authors.forename: Kathy J
authors.initials: KJ
authors.lastname: Helzlsouer
authors.forename: Marjorie L
authors.initials: ML
authors.lastname: McCullough
authors.forename: V Wendy
authors.initials: VW
authors.lastname: Setiawan
authors.forename: Xiao-Ou
authors.initials: XO
authors.lastname: Shu
authors.forename: Stephanie J
authors.initials: SJ
authors.lastname: Weinstein
authors.forename: Jocelyn M
authors.initials: JM
authors.lastname: Weiss
authors.forename: Alan A
authors.initials: AA
authors.lastname: Arslan
authors.forename: Immaculata
authors.initials: I
authors.lastname: De Vivo
authors.forename: Yu-Tang
authors.initials: YT
authors.lastname: Gao
authors.forename: Richard B
authors.initials: RB
authors.lastname: Hayes
authors.forename: Brian E
authors.initials: BE
authors.lastname: Henderson
authors.forename: Ronald L
authors.initials: RL
authors.lastname: Horst
authors.forename: Karen L
authors.initials: KL
authors.lastname: Koenig
authors.forename: Alpa V
authors.initials: AV
authors.lastname: Patel
authors.forename: Mark P
authors.initials: MP
authors.lastname: Purdue
authors.forename: Kirk
authors.initials: K
authors.lastname: Snyder
authors.forename: Emily
authors.initials: E
authors.lastname: Steplowski
authors.forename: Kai
authors.initials: K
authors.lastname: Yu
authors.forename: Wei
authors.initials: W
authors.lastname: Zheng
authors.forename: Susan E
authors.initials: SE
authors.lastname: Hankinson
mesh_terms: D000328:Adult; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D015331:Cohort Studies; D016889:Endometrial Neoplasms / Q000453:epidemiology* / Q000517:prevention & control; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D016015:Logistic Models; D011446:Prospective Studies; D012307:Risk Factors; D014481:United States / Q000453:epidemiology; D014807:Vitamin D / Q000097:blood* / Q000627:therapeutic use*; D014808:Vitamin D Deficiency / Q000150:complications* / Q000453:epidemiology / Q000517:prevention & control
chemical_list: D014807:Vitamin D